| 1 |
Radin M, Cecchi I, Arbrile M, Montin D, Farinasso L, Cioffi M, Foddai SG, Barinotti A, Menegatti E, Baldovino S, Sciascia S, Roccatello D. Pediatric Presentation of Antiphospholipid Syndrome: A Review of Recent Literature With Estimation of Local Prevalence. Semin Thromb Hemost 2023. [PMID: 36940717 DOI: 10.1055/s-0043-1764472] [Reference Citation Analysis]
|
| 2 |
Kalashnikova EM, Raupov RK, Lyubimova NA, Kuchinskaya EM, Masalova VV, Isupova EA, Gaidar EV, Dubko MF, Snegireva LS, Sorokina LS, Kornishina TL, Kaneva MA, Chikova IA, Likhacheva TS, Kolobova OL, Kalashnikova OV, Chasnyk VG, Kostik MM. The experience of rituximab therapy in patients with juvenile systemic lupus erythematosus: the preliminary results of two-center cohort study. Ross vestn perinatol pediatr 2023;68:74-84. [DOI: 10.21508/1027-4065-2023-68-1-74-84] [Reference Citation Analysis]
|
| 3 |
Lv J, Liu L, Hao C, Li G, Fu P, Xing G, Zheng H, Chen N, Wang C, Luo P, Xie D, Zuo L, Li R, Mao Y, Dong S, Zhang P, Zheng H, Wang Y, Qin W, Wang W, Li L, Jiao W, Fang J, Zhang H. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. Kidney Int Rep 2023;8:499-506. [PMID: 36938094 DOI: 10.1016/j.ekir.2022.12.014] [Reference Citation Analysis]
|
| 4 |
Li Z, Wang J, Huang Y, Shen Q, Sun L, Xu H, Li Z. Identification of biomarkers that predict renal flare in childhood-onset lupus nephritis with mycophenolate acid. Int Immunopharmacol 2023;117:109900. [PMID: 36863143 DOI: 10.1016/j.intimp.2023.109900] [Reference Citation Analysis]
|
| 5 |
Liu X, Peng Y, Cai S. The efficacy and safety of cyclosporine in children with systemic lupus erythematosus: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2023;102:e32314. [PMID: 36827060 DOI: 10.1097/MD.0000000000032314] [Reference Citation Analysis]
|
| 6 |
Contigli C, Valle MS, Oloris SCS, Pimenta LPS, Takahashi JA. Polyketides from Fungi. Natural Secondary Metabolites 2023. [DOI: 10.1007/978-3-031-18587-8_17] [Reference Citation Analysis]
|
| 7 |
Wang Y, Xie X, Zheng S, Du G, Chen S, Zhang W, Zhuang J, Lin J, Hu S, Zheng K, Mikish A, Xu Z, Zhang G, Gargani L, Bruni C, Hoffmann-Vold AM, Matucci-Cerinic M, Furst DE. Serum B-cell activating factor and lung ultrasound B-lines in connective tissue disease related interstitial lung disease. Front Med (Lausanne) 2022;9:1066111. [PMID: 36590969 DOI: 10.3389/fmed.2022.1066111] [Reference Citation Analysis]
|
| 8 |
Xie Z, Li Q, Dai X, Ye X. Tacrolimus reverses pemphigus vulgaris serum-enhanced expression of desmoglein in HaCaT cells via inhibition of heat shock protein-27 phosphorylation.. [DOI: 10.21203/rs.3.rs-2307010/v1] [Reference Citation Analysis]
|
| 9 |
Liu J, Song W, Cui D. Relationship between Blood Lipid Profiles and Risk of Lupus Nephritis in Children. International Journal of Clinical Practice 2022;2022:1-6. [DOI: 10.1155/2022/6130774] [Reference Citation Analysis]
|
| 10 |
Rojas-rivera JE, García-carro C, Ávila AI, Espino M, Espinosa M, Fernández-juárez G, Fulladosa X, Goicoechea M, Macía M, Morales E, Quintana Porras LF, Praga M. Documento de consenso del Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN) para el diagnóstico y tratamiento de la nefritis lúpica. Nefrología 2022. [DOI: 10.1016/j.nefro.2022.10.005] [Reference Citation Analysis]
|
| 11 |
Wu J, Yang W, Li H. An artificial neural network model based on autophagy-related genes in childhood systemic lupus erythematosus. Hereditas 2022;159. [DOI: 10.1186/s41065-022-00248-7] [Reference Citation Analysis]
|
| 12 |
Kadhim Abbas H, Jabbar Kadhim D, Isho Gorial F, Shareef LG. Assessment of medication-related burden among a sample of Iraqi patients with systemic lupus erythematosus and its relationship with disease activity: a cross-sectional study. F1000Res 2022;11:970. [DOI: 10.12688/f1000research.124698.1] [Reference Citation Analysis]
|
| 13 |
Lu Y, Huang XM. Autoimmune hemolytic anemia as an initial presentation in children with systemic lupus erythematosus: two case reports. J Int Med Res 2022;50:3000605221115390. [PMID: 35971316 DOI: 10.1177/03000605221115390] [Reference Citation Analysis]
|
| 14 |
Chen F, Zheng Y, Chen X, Wen Z, Xu Y, Yang J, Xu K. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol 2022;13:940416. [DOI: 10.3389/fimmu.2022.940416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Hussain A, Maheshwari MV, Khalid N, Patel PD, Alghareeb R. Diagnostic Delays and Psychosocial Outcomes of Childhood-Onset Systemic Lupus Erythematosus. Cureus 2022. [DOI: 10.7759/cureus.26244] [Reference Citation Analysis]
|
| 16 |
Soliman SA, Haque A, Vanarsa K, Zhang T, Ismail F, Lee KH, Pedroza C, Greenbaum LA, Mason S, Hicks MJ, Wenderfer SE, Mohan C. Urine ALCAM, PF4 and VCAM-1 Surpass Conventional Metrics in Identifying Nephritis Disease Activity in Childhood-Onset Systemic Lupus Erythematosus. Front Immunol 2022;13:885307. [PMID: 35720325 DOI: 10.3389/fimmu.2022.885307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H, Zhao F, Yu H, Qiu L, Li X, He X, Chen Y, Xu Z, Xu H. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before–after trial. Lupus. [DOI: 10.1177/09612033221097812] [Reference Citation Analysis]
|
| 18 |
Deng WP. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children. Zhongguo Dang Dai Er Ke Za Zhi 2021;23:1069-74. [PMID: 34719425 DOI: 10.7499/j.issn.1008-8830.2107153] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
